Recent studies have focused on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopamine signaling. While GCGR stimulators are commonly employed for treating type 2 diabetes mellitus, their emerging impacts on motivation circuits, specifically influenced by dopamine systems, are gaining considerable